# The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

> **NCT07028632** · PHASE2 · NOT_YET_RECRUITING · sponsor: **iRegene Therapeutics Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Parkinson Disease (PD)

## Interventions

- **BIOLOGICAL:** Human Dopaminergic Progenitor Cells

## Key facts

- **NCT ID:** NCT07028632
- **Lead sponsor:** iRegene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028632, "The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07028632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*